Lexeo Therapeutics Inc
LXEO4.810USD
+0.200+4.34%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
159.66MCap. mercado
PérdidaP/E TTM
Más Datos de Lexeo Therapeutics Inc Compañía
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Información de la empresa
Símbolo de cotizaciónLXEO
Nombre de la empresaLexeo Therapeutics Inc
Fecha de salida a bolsaNov 03, 2023
Director ejecutivoMr. R. Nolan Townsend
Número de empleados72
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 03
Dirección345 Park Avenue South
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal10010
Teléfono12125479879
Sitio Webhttps://www.lexeotx.com/
Símbolo de cotizaciónLXEO
Fecha de salida a bolsaNov 03, 2023
Director ejecutivoMr. R. Nolan Townsend
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kyle Rasbach
Dr. Kyle Rasbach
Chief Financial Officer
Chief Financial Officer
40.88K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
5.46K
-9.69%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Paula H. J. Cholmondeley
Ms. Paula H. J. Cholmondeley
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jenny R. Robertson, J.D.
Ms. Jenny R. Robertson, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kyle Rasbach
Dr. Kyle Rasbach
Chief Financial Officer
Chief Financial Officer
40.88K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
5.46K
-9.69%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Desglose de ingresos
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
13.73%
Frazier Life Sciences Management, L.P.
13.33%
Affinity Asset Advisors LLC
10.20%
Longitude Capital Management Co., LLC
8.33%
Citadel Advisors LLC
8.20%
Other
46.21%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
13.73%
Frazier Life Sciences Management, L.P.
13.33%
Affinity Asset Advisors LLC
10.20%
Longitude Capital Management Co., LLC
8.33%
Citadel Advisors LLC
8.20%
Other
46.21%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
41.71%
Investment Advisor/Hedge Fund
26.11%
Investment Advisor
16.31%
Venture Capital
16.20%
Private Equity
13.81%
Research Firm
7.22%
Individual Investor
0.87%
Bank and Trust
0.08%
Pension Fund
0.02%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
180
40.62M
122.36%
+311.25K
2025Q1
174
34.46M
103.80%
-3.48M
2024Q4
155
35.40M
107.08%
+416.99K
2024Q3
127
33.64M
101.76%
+2.87M
2024Q2
112
31.41M
96.45%
+1.88M
2024Q1
92
30.30M
97.67%
+5.87M
2023Q4
45
23.22M
87.68%
+3.57M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
4.56M
13.73%
+218.67K
+5.04%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
4.42M
13.33%
+3.47M
+363.07%
May 28, 2025
Affinity Asset Advisors LLC
3.38M
10.2%
+1.90M
+128.56%
May 28, 2025
Longitude Capital Management Co., LLC
2.77M
8.33%
--
--
Sep 30, 2024
Citadel Advisors LLC
2.72M
8.2%
--
--
Mar 31, 2025
Mizuho Securities USA, LLC.
2.20M
6.64%
+276.70K
+14.36%
Mar 31, 2025
Millennium Management LLC
1.93M
5.82%
+861.89K
+80.44%
Apr 22, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
5.17%
+48.42K
+2.90%
Mar 31, 2025
Omega Fund Management, LLC
1.18M
3.57%
--
--
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.16M
3.49%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Health Innovation Active ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
iShares Health Innovation Active ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
